University of Oxford

AstraZeneca Says Its COVID-19 Vaccine Candidate Has 90% Efficacy

COVID-19 Reinfection Unlikely for at Least Six Months: Study

J&J Pauses COVID-19 Vaccine Trials Over Unexplained Illness in Participant

There’s a New Outbreak – of Vaccine Nationalism

Will the COVID-19 Pandemic Change the IP Domain for the Better?